Results 21 to 30 of about 267,118 (262)

RXR Agonists Enhance Lenalidomide Anti-Myeloma Activity and T Cell Functions while Retaining Glucose-Lowering Effect

Cells, 2023
Retinoid X receptor (RXR) heterodimerizes with the PPAR nuclear hormone receptor and regulates its downstream events. We investigated the effects of RXR agonists (LG100754, bexarotene, AGN194204, and LG101506) on lenalidomide’s anti-myeloma activity, T ...
Jian Wu, Xiaobei Wang, Min Zhang, Parker Mathews, Yubin Kang   +4 more
doaj   +1 more source

Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9

Nature Communications, 2020
Antigen-specific IL9-secreting CD4 Th9 and CD8 Tc9 cells have been previously characterized for their anti-tumour properties. Here, the authors show that ex vivo polarized Th9/Tc9 human CAR-T cells display increased anti-tumor activity in pre-clinical ...
Lintao Liu, Enguang Bi, Xingzhe Ma, Wei Xiong, Jianfei Qian, Lingqun Ye, Pan Su, Qiang Wang, Liuling Xiao, Maojie Yang, Yong Lu, Qing Yi   +11 more
doaj   +1 more source

Top 100 Cited Articles on Clinical Hematopoietic Stem Cell Transplantation: A Bibliometric Analysis

Frontiers in Medicine, 2022
We conducted a bibliometric analysis to identify scholarly impact and factors associated with the top 100 cited articles on clinical hematopoietic stem cell transplantation (HSCT). In January 2021, a title-specific search was conducted.
Moazzam Shahzad, Moazzam Shahzad, Sibgha Gull Chaudhary, Iqra Anwar, Muhammad Arslan, Zehra Naseem, Naira T. Fatima, Sakina Abbas, Tayyaba Ali, Raheel S. Siddiqui, Peiman Hematti, Sunil H. Abhyankar, Joseph P. McGuirk, Muhammad Umair Mushtaq   +13 more
doaj   +1 more source

Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results

Haematologica, 2018
Aprior phase I/II trial of bortezomib/tacrolimus/methotrexate prophylaxis after human leukocyte antigen (HLA)-mismatched reduced intensity conditioning allogeneic hematopoietic stem cell transplantation documented low acute graft-versus-host disease ...
John Koreth, Haesook T. Kim, Paulina B. Lange, Samuel J. Poryanda, Carol G. Reynolds, Sharmila Chamling Rai, Philippe Armand, Corey S. Cutler, Vincent T. Ho, Brett Glotzbecker, Rushdia Yusuf, Sarah Nikiforow, Yi-Bin Chen, Bimalangshu Dey, Malgorzata McMasters, Jerome Ritz, Bruce R. Blazar, Robert J. Soiffer, Joseph H. Antin, Edwin P. Alyea   +19 more
doaj   +1 more source

Stimulation of Potent Humoral and Cellular Immunity via Synthetic Dual-Antigen MVA-Based COVID-19 Vaccine COH04S1 in Cancer Patients Post Hematopoietic Cell Transplantation and Cellular Therapy

Vaccines, 2023
Hematopoietic cell transplantation (HCT) and chimeric antigen receptor (CAR)-T cell patients are immunocompromised, remain at high risk following SARS-CoV-2 infection, and are less likely than immunocompetent individuals to respond to vaccination.
Flavia Chiuppesi, Sandra Ortega-Francisco, Miguel-Angel Gutierrez, Jing Li, Minh Ly, Katelyn Faircloth, Jada Mack-Onyeike, Corinna La Rosa, Sandra Thomas, Qiao Zhou, Jennifer Drake, Cynthia Slape, Paolo Fernando, Wasima Rida, Teodora Kaltcheva, Alba Grifoni, Alessandro Sette, Angela Patterson, Shannon Dempsey, Brian Ball, Haris Ali, Amandeep Salhotra, Anthony Stein, Nitya Nathwani, Michael Rosenzweig, Liana Nikolaenko, Monzr M. Al Malki, Jana Dickter, Deepa D. Nanayakkara, Alfredo Puing, Stephen J. Forman, Randy A. Taplitz, John A. Zaia, Ryotaro Nakamura, Felix Wussow, Don J. Diamond, Sanjeet S. Dadwal   +36 more
doaj   +1 more source

Immunotherapy in Hematologic Malignancies

, 2020
The management of hematologic malignancies has traditionally relied on chemotherapy regimens, many of which are still in use today. However, with advancements in the knowledge of tumour pathophysiology, therapies are continually evolving.
C. Speziali, R.R. Kansara
core   +1 more source

New developments in immunotherapy for lymphoma

Cancer Biology & Medicine, 2018
The development of immunotherapies for lymphoma has undergone a revolutionary evolution over the past decades. Since the advent of rituximab as the first successful immunotherapy for B-cell non-Hodgkin lymphoma over two decades ago, a plethora of new ...
Benjamin Heyman, Yiping Yang
doaj   +1 more source

Febrile Neutropenia in Hematologic Malignancies

, 2013
Febrile neutropenia (FN) can occur at any time during the course of a malignancy, especially hematologic malignancies, from diagnosis to end-stage disease.
Sekeres, Mikkael A., Keng, Michael K.
core   +1 more source

Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML

Blood Neoplasia
: Patients with nucleophosmin 1 (NPM1)–mutated acute myeloid leukemia (AML) without a FLT3-internal tandem duplication mutation are considered to have favorable-risk disease that may be cured with intensive chemotherapy (7+3; IC) alone.
Andrew D Zale, Venkata Preetam Sandeep Kaduluri, Jonathan A Webster, Mark J Levis, Ivana Gojo, Amy E DeZern, Gabriel Ghiaur, Lukasz P Gondek, William Brian Dalton, Theodoros Karantanos, Tania Jain, Gabrielle T Prince, Richard J Jones, B. Douglas Smith, Alexander J Ambinder   +14 more
doaj   +1 more source

Outcomes with chimeric antigen receptor t-cell therapy in relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis

Frontiers in Immunology, 2023
BackgroundWe conducted a systematic review and meta-analysis to evaluate outcomes following chimeric antigen receptor T cell (CAR-T) therapy in relapsed/refractory acute myeloid leukemia (RR-AML).MethodsWe performed a literature search on PubMed ...
Moazzam Shahzad, Moazzam Shahzad, Andrea Nguyen, Ali Hussain, Mohammad Ammad-Ud-Din, Muhammad Salman Faisal, Ezza Tariq, Fatima Ali, Atif Butt, Iqra Anwar, Sibgha Gull Chaudhary, Forat Lutfi, Nausheen Ahmed, Anurag K. Singh, Peiman Hematti, Joseph P. McGuirk, Muhammad Umair Mushtaq   +16 more
doaj   +1 more source